API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
Listed Suppliers
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.astrazeneca.com/media-centre/press-releases/2024/calquence-fixed-duration-combo-improved-1l-cll-pfs.html
https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-aims-deliver-80-billion-total-revenue-by-2030-2024-05-21/
https://www.astrazeneca.com/media-centre/press-releases/2024/calquence-combination-improved-pfs-in-1l-mcl.html
https://www.pharmacompass.com/pdf/news/fda-confirms-para-iv-patent-litigation-for-acalabrutinib-maleate-calquence-tablets-49711.pdf
https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-beats-first-quarter-revenue-profit-estimates-2024-04-25/
https://www.prnewswire.com/news-releases/ascentage-pharma-and-astrazeneca-enter-into-clinical-collaboration-on-the-registrational-phase-iii-study-of-bcl-2-inhibitor-lisaftoclax-in-combination-with-btk-inhibitor-acalabrutinib-in-treatment-naive-patients-with-first-line-cl-301956934.html
https://www.europeanpharmaceuticalreview.com/news/179773/astrazeneca-btk-inhibitor-tablet-approved-in-eu-for-leukaemia/#:~:text=AstraZeneca's%20tablet%20formulation%20of%20Calquence,to%20BTK%2C%20inhibiting%20its%20activity
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216775
https://www.globenewswire.com/news-release/2021/12/09/2349194/0/en/Aprea-Therapeutics-Announces-Removal-of-FDA-Clinical-Hold-on-Eprenetapopt-in-Lymphoid-Malignancies.html
https://endpts.com/astrazeneca-promotes-oncology-exec-to-cmo-pfizer-replaces-retiring-chief-dealmaker-as-war-chest-expands/
https://www.businesswire.com/news/home/20210607005222/en/CALQUENCE-Demonstrated-Fewer-Incidences-of-Atrial-Fibrillation-Versus-Ibrutinib-in-Previously-Treated-Patients-With-Chronic-Lymphocytic-Leukemia-and-Sustained-Patient-Benefit-at-Four-Years-in-the-Front-line-Setting
http://www.pharmatimes.com/news/nice_backs_astrazenecas_calquence_for_cll_1365452
https://www.nice.org.uk/news/article/chemotherapy-free-treatment-option-to-be-offered-to-patients-with-england-s-most-common-leukaemia
https://www.biopharmadive.com/news/astrazeneca-calquence-imbruvica-leukemia-study/593888/
https://www.fiercepharma.com/marketing/astrazeneca-touts-safer-calquence-against-imbruvica-leukemia-trial-showdown
https://www.astrazeneca.com/media-centre/press-releases/2021/calquence-met-primary-endpoint-against-ibrutinib.html
http://www.pharmatimes.com/news/nice_backs_az_calquence_for_chronic_lymphocytic_leukaemia_1359305
https://www.fiercepharma.com/pharma/ash-astrazeneca-s-calquence-beigene-s-brukinsa-turn-heads-new-data-putting-imbruvica-notice
https://www.businesswire.com/news/home/20201207005217/en/CALQUENCE-Data-Across-Four-Trials-Reinforces-Cardiovascular-Safety-Profile-in-Patients-With-Chronic-Lymphocytic-Leukemia
http://www.pharmatimes.com/news/calquence_shows_long-term_efficacy_and_tolerability_in_mcl_1359178
https://www.europeanpharmaceuticalreview.com/news/133330/calquence-fails-to-prevent-respiratory-failure-in-covid-19-patients/
https://www.pharmtech.com/view/calquence-gains-eu-approval-for-treatment-of-chronic-lymphocytic-leukemia
http://www.pharmatimes.com/news/eu_ok_for_azs_calquence_in_cll_1356447
https://economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/icmr-approaches-experts-panel-to-approve-testing-of-cancer-drug-acalabrutinib-for-covid-treatment/articleshow/78653314.cms
https://www.raps.org/news-and-articles/news-articles/2020/7/ema-thumbs-up-for-11-down-for-2-new-medicines
https://www.newswise.com/coronavirus/john-theurer-cancer-center-part-of-a-new-study-in-covid19-patients-suggesting-activity-of-a-novel-agent-btk-inhibitor-acalabrutinib-used-as-anti-cancer-drug-in-b-cell-malignancies/?article_id=734619
https://www.astrazeneca.com/media-centre/press-releases/2020/calquence-showed-long-term-efficacy-and-tolerability-for-patients-with-chronic-lymphocytic-leukaemia-in-two-trials.html
https://www.reuters.com/article/us-health-coronavirus-astrazeneca/astrazeneca-blood-cancer-drug-shows-signs-of-helping-covid-19-patients-idUSKBN23C2P4?feedType=RSS&feedName=healthNews
http://www.pharmatimes.com/news/az_calquence_shows_promise_for_covid-19_1341849
https://www.forbes.com/sites/nathanvardi/2020/06/05/astrazenecas-calquence-showed-improvement-in-small-group-of-hospitalized-covid-19-patients/#7cd1a037539f
https://www.reuters.com/article/us-health-coronavirus-astrazeneca/astrazeneca-blood-cancer-drug-shows-signs-of-helping-covid-19-patients-idUSKBN23C2P4
https://www.theguardian.com/world/2020/jun/01/uk-hospitals-trial-five-new-drugs-search-coronavirus-treatment
https://www.fiercepharma.com/pharma-asia/beigene-s-new-btk-drug-brukinsa-disappoints-as-pd-1-tislelizumab-shines-busy-quarter
https://www.cambridgeindependent.co.uk/news/astrazeneca-begins-clinical-trial-of-blood-cancer-drug-calquence-for-covid-19-patients-9107048/
https://www.reuters.com/article/us-health-coronavirus-astrazeneca/astrazeneca-to-start-calquence-in-covid-19-trial-idUSKCN21W0MG
https://www.forbes.com/sites/nathanvardi/2020/04/13/exclusive-astrazenecas-calquence-shows-early-promise-for-covid-19-patients/#423c45264677
http://www.pmlive.com/pharma_news/ema_begins_review_of_kites_car-t_for_mantle_cell_lymphoma_1323675
https://www.fiercepharma.com/marketing/ash-follow-up-survey-finds-physician-enthusiasm-around-car-t-off-shelf-therapies-and-btk
https://www.fiercepharma.com/marketing/ash-follow-up-survey-finds-physician-enthusiasm-around-car-t-off-shelf-therapies-and-btk
https://www.fiercepharma.com/marketing/ash-follow-up-survey-finds-physician-enthusiasm-around-car-t-off-shelf-therapies-and-btk